NO20064642L - Anvendelse av (S,S)- eller racemisk reboxetin - Google Patents

Anvendelse av (S,S)- eller racemisk reboxetin

Info

Publication number
NO20064642L
NO20064642L NO20064642A NO20064642A NO20064642L NO 20064642 L NO20064642 L NO 20064642L NO 20064642 A NO20064642 A NO 20064642A NO 20064642 A NO20064642 A NO 20064642A NO 20064642 L NO20064642 L NO 20064642L
Authority
NO
Norway
Prior art keywords
pain
medicament
manufacture
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20064642A
Other languages
English (en)
Inventor
Bernadette Hughes
Ian Mckenzie
Malcolm John Stoker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20064642L publication Critical patent/NO20064642L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Det beskrives anvendelse av (S,S)- eller racemisk reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for behandling av en smertetilstand valgt blant neuropatisk smerte, nociceptiv smerte, cancersmerte, ryggsmerte, inflammatorisk smerte, muskelskjelettsmerte, visceral smerte, smerte fra spenning/vrikking, postoperativ smerte, posttraumatisk smerte, brannskader, renal kolikk, akutt smerte, sentralnervesystemtraume, hodesmerte og orofacial smerte. Anvendelse av (S,S)- reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for behandling av smerte i en pasient refraktær til en alfa-2-delta ligand og anvendelse av (S,S)- eller racemisk reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for anvendelse for mental prestasjon eller som sinnsstemningsforbedrer beskrives også.
NO20064642A 2004-06-09 2006-10-12 Anvendelse av (S,S)- eller racemisk reboxetin NO20064642L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
NO20064642L true NO20064642L (no) 2006-11-13

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064642A NO20064642L (no) 2004-06-09 2006-10-12 Anvendelse av (S,S)- eller racemisk reboxetin

Country Status (12)

Country Link
US (1) US20080261984A1 (no)
EP (1) EP1763354A2 (no)
JP (1) JP2008501778A (no)
KR (1) KR20070029740A (no)
AU (1) AU2005256944A1 (no)
BR (1) BRPI0511941A (no)
CA (1) CA2567365A1 (no)
IL (1) IL178827A0 (no)
MX (1) MXPA06014389A (no)
NO (1) NO20064642L (no)
RU (1) RU2006143659A (no)
WO (1) WO2006000903A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20210177881A1 (en) * 2018-04-17 2021-06-17 Shanghai Tonglian Pharmaceutical Co., Ltd. Medicament for preventing and/or treating pain and/or fever, composite product and use thereof
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
US20190381056A1 (en) * 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
MX2021004207A (es) * 2018-10-15 2021-08-11 Axsome Therapeutics Inc Uso de reboxetina para el tratamiento de narcolepsia.
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1459751B1 (en) * 1999-07-01 2005-09-14 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating migraine headaches
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1667686A1 (en) * 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern

Also Published As

Publication number Publication date
BRPI0511941A (pt) 2008-01-22
WO2006000903A2 (en) 2006-01-05
AU2005256944A1 (en) 2006-01-05
EP1763354A2 (en) 2007-03-21
WO2006000903A3 (en) 2006-06-08
IL178827A0 (en) 2007-03-08
CA2567365A1 (en) 2006-01-05
MXPA06014389A (es) 2007-02-19
RU2006143659A (ru) 2008-06-20
KR20070029740A (ko) 2007-03-14
US20080261984A1 (en) 2008-10-23
JP2008501778A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
NO20064642L (no) Anvendelse av (S,S)- eller racemisk reboxetin
EA200900072A1 (ru) Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
IS8230A (is) Setið 2-amínótetralín til notkunar við meðferð á þunglyndi
JP2008501778A5 (no)
JO2282B1 (en) Oxazole derivatives
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
TW200621765A (en) Substituted phenylaminothiazoles and their use
EA201070046A1 (ru) Способ получения лекарственного средства, содержащего тадалафил
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
GEP20125565B (en) Lactam compounds and their pharmaceutical use
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
RU2008127882A (ru) Лечение пищевода барретта
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
RU2007122391A (ru) S-миртазапин для лечения приливов
DE602007014400D1 (de) Behandlung pervasiver entwicklungsstörungen
RU2015105821A (ru) Способ адъювантного лечения рака
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ATE429435T1 (de) 7h-pyrrolopyrimidinderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application